These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20733133)

  • 1. Risk of arterial thrombosis not increased by sorafenib or sunitinib.
    Minor DR
    J Clin Oncol; 2010 Oct; 28(30):e619; author reply e620. PubMed ID: 20733133
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J
    J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cutaneous side effects of sorafenib and sunitinib].
    Autier J; Mateus C; Wechsler J; Spatz A; Robert C
    Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F
    Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
    [No Abstract]   [Full Text] [Related]  

  • 5. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD
    J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341
    [No Abstract]   [Full Text] [Related]  

  • 6. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
    Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
    Thyroid; 2009 May; 19(5):539-40. PubMed ID: 19416001
    [No Abstract]   [Full Text] [Related]  

  • 7. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
    J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract]   [Full Text] [Related]  

  • 8. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk of bleeding not increased by sorafenib or sunitinib.
    Minor DR
    Lancet Oncol; 2010 Feb; 11(2):112-3; author reply 113. PubMed ID: 20152763
    [No Abstract]   [Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
    Lenihan DJ
    J Clin Oncol; 2008 Nov; 26(32):5154-5. PubMed ID: 18838702
    [No Abstract]   [Full Text] [Related]  

  • 11. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
    Berchem G; Dewilde S; Mahassen P
    Bull Soc Sci Med Grand Duche Luxemb; 2009; (1):7-9. PubMed ID: 19514172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
    Overkleeft EN; Goldschmeding R; van Reekum F; Voest EE; Verheul HM
    Ann Oncol; 2010 Jan; 21(1):184-5. PubMed ID: 19889617
    [No Abstract]   [Full Text] [Related]  

  • 14. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
    [No Abstract]   [Full Text] [Related]  

  • 15. Sorafenib: muscle wasting.
    Prescrire Int; 2011 Dec; 20(122):296-7. PubMed ID: 22216546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible cardiomyopathy associated with sunitinib and sorafenib.
    Uraizee I; Cheng S; Moslehi J
    N Engl J Med; 2011 Oct; 365(17):1649-50. PubMed ID: 22030001
    [No Abstract]   [Full Text] [Related]  

  • 17. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
    Feldt S; Schüssel K; Quinzler R; Franzmann A; Czeche S; Ludwig WD; Schulz M
    Eur J Cancer; 2012 May; 48(7):974-81. PubMed ID: 22382202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
    Turan N; Benekli M; Ozturk SC; Inal S; Memis L; Guz G; Cetin B; Buyukberber S
    Ann Pharmacother; 2012 Oct; 46(10):e27. PubMed ID: 23032654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.